The PLGF data collected in motesanib phase 2 studies [8], [18]–[20] formed a strong body of evidence that supported further prospective testing of PLGF as a potential biomarker in the large international phase 3 Motesanib NSCLC Efficacy and Tolerability (MONET1) study of motesanib plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel in patients with nonsquamous NSCLC. The gene discussed is PGF; the disease is non-small cell lung carcinoma.